胃癌腹膜转移的治疗进展  

Treatment Advances of Peritoneal Metastasis from Gastric Cancer

作　　者：谭伊诺[1] 袁瑛[1,2] 

机构地区：[1]浙江大学医学院附属第二医院肿瘤内科,杭州310009 [2]恶性肿瘤预警与干预教育部重点实验室,医学分子生物学重点实验室,杭州310009

出　　处：《肿瘤防治研究》2015年第5期506-510,共5页Cancer Research on Prevention and Treatment

摘　　要：尽管胃癌的治疗策略和方法在不断进步,胃癌患者的预后在逐步改善,但胃癌腹膜转移患者的预后仍非常差,故需不断探索有效的治疗措施和药物。目前全身化疗仍是基础,常用药物有替吉奥(S-1)、紫杉类、铂类等,而腹腔灌注化疗中应用紫杉醇、顺铂、多西他赛等药物也有临床试验显示出一定的疗效。细胞减灭术联合腹腔热灌注化疗可在部分患者中有生存获益甚至获得长期生存。上皮细胞黏附分子Ep CAM,腹膜转移普遍表达的靶点,其特异性单抗Catumaxomab可能在胃癌腹膜转移中具有应用前景。本文对胃癌伴腹膜转移的诊疗进展进行回顾总结。Although the treatment of gastric cancer is advancing, the clinical outcome is gradually improving, the survival of gastric cancer patients with peritoneal metastasis is still very poor. Effective drugs and strategies against peritoneal metastasis are needed. Now, systemic chemotherapy is the basics, commonly used drugs include S-1, paclitaxel and platinum, etc.. Intraperitoneal chemotherapy with paclitaxel, platinum and docetaxel could also be effective. Cytoreductive surgery combined with intraperitoneal chemotherapy could bring some patients survival benefit, even long-term survival. Peritoneal metastatic lesions showed high levels of epithelial cellular adhesion molecule(Ep CAM), an anti-Ep CAM monoclonal antibody, Catumaxomab, may be effective against peritoneal metastasis from gastric cancer. In this paper, we review the treatment advances of peritoneal metastasis from gastric cancer.

关 键 词：胃癌 腹膜转移 紫杉醇 替吉奥(S-1) 腹腔灌注化疗 细胞减灭术 

分 类 号：R735.2[医药卫生—肿瘤]